53 related articles for article (PubMed ID: 2092110)
1. Soluble interleukin-2 receptor: a new prognostic marker in lung cancer.
Marino P; Buccheri G; Preatoni A; Ferrigno D; Cori P; Rosti A; Mozzi R; Moroni GA
J Nucl Med Allied Sci; 1990; 34(4 Suppl):151-4. PubMed ID: 2092110
[No Abstract] [Full Text] [Related]
2. Interleukin 2 soluble receptor (s-IL 2R) and lung cancer.
Pecchio F; Rapellino M; Aimo G; Baldi S; Cunazza M; Libertucci D; Cavallo A; Oliaro A; Pagni R
J Nucl Med Allied Sci; 1990; 34(4 Suppl):163-7. PubMed ID: 2092112
[No Abstract] [Full Text] [Related]
3. [The value of measuring the serum level of soluble interleukin-2 receptors in lung cancer patients].
Siemińska A
Pol Merkur Lekarski; 2004 Feb; 16(92):188-90. PubMed ID: 15176308
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
5. The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer.
McKeown DJ; Brown DJ; Kelly A; Wallace AM; McMillan DC
Br J Cancer; 2004 Dec; 91(12):1993-5. PubMed ID: 15570310
[TBL] [Abstract][Full Text] [Related]
6. Soluble immunological parameters and early prognosis of renal cell cancer patients.
Kallio JP; Tammela TL; Marttinen AT; Kellokumpu-Lehtinen PL
J Exp Clin Cancer Res; 2001 Dec; 20(4):523-8. PubMed ID: 11876546
[TBL] [Abstract][Full Text] [Related]
7. Serum soluble interleukin 2 receptor in patients with IgA nephropathy.
Yorioka N; Hirabayashi A; Takemasa A; Kanahara K; Takahashi N; Oda H; Joarder ZH; Harada S; Yamakido M
Hiroshima J Med Sci; 1989 Dec; 38(4):169-71. PubMed ID: 2637244
[TBL] [Abstract][Full Text] [Related]
8. Circulating levels of soluble CD30 and other markers in colorectal cancer patients.
Iwagaki H; Hizuta A; Kohka H; Kobashi K; Nitta Y; Isozaki H; Takakura N; Tanaka N
J Med; 1999; 30(1-2):111-21. PubMed ID: 10515247
[TBL] [Abstract][Full Text] [Related]
9. Prognostic relevance of soluble interleukin-2 receptors in patients with ovarian tumors.
Gebauer G; Rieger M; Jäger W; Lang N
Anticancer Res; 1999; 19(4A):2509-11. PubMed ID: 10470184
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic factors in patients with stage III and IV non-small cell lung cancer].
Song LH; Song XR; Liu MQ; Zhang XQ; Zheng L; Li XJ; Liu PX
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):345-8. PubMed ID: 15312344
[TBL] [Abstract][Full Text] [Related]
11. [Correlation between the tumor marker Pro-GRP and prognosis in patients with small-cell lung cancer].
Tsuchiyama T; Kawahara M; Naka N; Yamamoto S; Nakao M; Kamimori T; Okada T; Atagi S; Ogawara M; Furuse K
Nihon Kyobu Shikkan Gakkai Zasshi; 1997 Jun; 35(6):616-21. PubMed ID: 9294294
[TBL] [Abstract][Full Text] [Related]
12. [Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma].
Pérez Encinas M; Bello JL; Bendaña A; Rabuñal MJ; González S; Abuín I; Noya M; Cadarso C
Med Clin (Barc); 1998 Jul; 111(5):161-7. PubMed ID: 9732831
[TBL] [Abstract][Full Text] [Related]
13. Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) detection in cancer patients: a prognostic marker for lung metastases from solid malignancies.
Karapanagiotou EM; Pelekanou E; Charpidou A; Tsaganos T; Anagnostou V; Plachouras D; Giamarellos-Bourboulis EJ; Syrigos KN
Anticancer Res; 2008; 28(2B):1411-5. PubMed ID: 18505088
[TBL] [Abstract][Full Text] [Related]
14. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer.
Joensuu H; Anttonen A; Eriksson M; Mäkitaro R; Alfthan H; Kinnula V; Leppä S
Cancer Res; 2002 Sep; 62(18):5210-7. PubMed ID: 12234986
[TBL] [Abstract][Full Text] [Related]
15. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer.
Ylisirniö S; Höyhtyä M; Mäkitaro R; Pääakkö P; Risteli J; Kinnula VL; Turpeenniemi-Hujanen T; Jukkola A
Clin Cancer Res; 2001 Jun; 7(6):1633-7. PubMed ID: 11410500
[TBL] [Abstract][Full Text] [Related]
16. Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies.
Nakase K; Tsuji K; Tamaki S; Tanigawa M; Ikeda T; Miyanishi E; Shiku H
Cancer Detect Prev; 2005; 29(3):256-9. PubMed ID: 15899555
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of soluble interleukin-2 receptor--a possible index of disease prognosis in systemic sclerosis.
Lis A; Brzezińska-Wcisło L; Rubisz-Brzezińska J; Kulawik I
Clin Exp Dermatol; 1997 Jan; 22(1):60-1. PubMed ID: 9330064
[No Abstract] [Full Text] [Related]
18. Soluble interleukin-2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma: results of a multivariate prospective study.
Tartour E; Deneux L; Mosseri V; Jaulerry C; Brunin F; Point D; Validire P; Dubray B; Fridman WH; Rodriguez J
Cancer; 1997 Apr; 79(7):1401-8. PubMed ID: 9083163
[TBL] [Abstract][Full Text] [Related]
19. [Level and significance of the soluble interleukin-2 receptor expression in serum of patients with bladder cancer].
Wen R; Xie S; Ma P
Zhonghua Wai Ke Za Zhi; 1996 Jan; 34(1):16-8. PubMed ID: 9275680
[TBL] [Abstract][Full Text] [Related]
20. [Orosomucoid prealbumin ratio in bronchopulmonary cancers].
Charet JC; Leprêtre A; Watine J; Jounieaux V; Aron C; Charet P
Ann Biol Clin (Paris); 1995; 53(3):131-4. PubMed ID: 7574097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
